ArticleNagoya journal of medical science2025
Long non-coding RNA taurine upregulated 1 regulates the progression of head and neck cancer.
Article in Nagoya journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taurine upregulated 1 (TUG1), whose function is associated with tumor development, is a relatively new long non-coding RNA. TUG1 is overexpressed in multiple types of cancers. However, in head and neck squamous cell carcinoma (HNSCC), the behavior of TUG1 has not yet been completely elucidated. Therefore, we aimed to clarify the function of TUG1 in HNSCC and develop a novel therapeutic target. We analyzed the expression levels of TUG1 in patients with HNSCC using The Cancer Genome Atlas dataset and human oral keratinocytes, and five HNSCC cell lines (HSC-4, Sa3, HSQ-89, SAS, and Ca9-22) through quantitative reverse-transcription polymerase chain reaction. The biological role of TUG1 in HNSCC was investigated using cell growth and migration assays with antisense oligonucleotides in Ca9-22 and SAS cell lines. TUG1 target genes were identified via microarray analysis. The TUG1 expression level was considerably higher in tumor than in normal tissues, and the same result was observed in human oral keratinocytes and all HNSCC cell lines. TUG1 knockdown dramatically inhibited cell proliferation and migration. Furthermore, we identified nemo-like kinase, which may change in tandem with TUG1 expression. Our findings indicate the possibility for targeting the TUG1-nemo-like kinase axis as a novel approach for the treatment of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.